Boosted Atazanavir and Truvada Given Once-Daily - BATON Study
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00224445 |
Recruitment Status
:
Completed
First Posted
: September 23, 2005
Last Update Posted
: January 10, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HIV Infections | Drug: Truvada Drug: Atazanavir Drug: Ritonavir | Phase 4 |
To determine the safety and efficacy (viral load suppression and cluster of differentiation 4 [CD4] changes) of a simple, once-daily (QD) antiretroviral (ARV) regimen consisting of a fixed-dose combination tablet containing Truvada combined with the protease inhibitor atazanavir (ATV) boosted with ritonavir (ATV/r).
To evaluate fasting glucose, insulin, C peptide and lipid panel (total cholesterol, high and low density lipoprotein cholesterol (HDL, LDL), and serum triglycerides) in subjects receiving Truvada and boosted atazanavir.
To evaluate adherence to a QD ARV regimen of Truvada and boosted atazanavir.
To evaluate steady-state plasma pharmacokinetics (PK) of Truvada and atazanavir in study subjects receiving Truvada and boosted atazanavir.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 100 participants |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Boosted Atazanavir and Truvada Given Once-Daily (BATON Study): A Phase 4 Study of Safety, Efficacy & Adherence in HIV Infected, Antiretroviral Naïve Subjects Treated With a Simple Once-Daily Regimen |
Study Start Date : | September 2005 |
Actual Primary Completion Date : | January 2007 |
Actual Study Completion Date : | January 2007 |

Arm | Intervention/treatment |
---|---|
Experimental: Truvada + Ritonavir-boosted Atazanavir
All participants received Truvada plus ritonavir-boosted atazanavir
|
Drug: Truvada
Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg tablet) administered orally once daily (QD)
Drug: Atazanavir
Atazanavir 300 mg (given as two 150-mg capsules) administered orally QD
Drug: Ritonavir
Ritonavir 100 mg capsule administered orally QD
|
- Determine the safety/efficacy (viral load suppression and CD4 changes) of a once-daily (QD) antiretroviral (ARV) regimen consisting of a fixed-dose combination tablet containing Truvada. [ Time Frame: Baseline to Week 48 ]
- To evaluate fasting glucose, insulin, C peptide and lipid panel (total cholesterol, high and low density lipoprotein cholesterol (HDL, LDL), and serum triglycerides) in subjects receiving Truvada and boosted atazanavir. [ Time Frame: Baseline to Week 48 ]
- To evaluate adherence to a QD ARV regimen of Truvada and boosted atazanavir. [ Time Frame: Baseline to Week 48 ]
- To evaluate steady-state plasma PK of Truvada & atazanavir in study subjects receiving Truvada and boosted atazanavir. [ Time Frame: Baseline to Week 48 ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Adult (greater than or equal to 18 years) male or non-pregnant female HIV 1- infected subjects regardless of race or ethnicity.
- Antiretroviral treatment-naïve.
- Plasma HIV 1 RNA greater than 1000 copies/mL (Roche Amplicor HIV 1 Monitor Test Version 1.5 Ultrasensitive method, with a reflex to Standard for results greater than 75,000 and dilution for results greater than 750,000). There are no CD4 criteria for study inclusion.
- Adequate renal function defined as a calculated creatinine clearance (CLCr) greater than or equal to 50 mL/min according to the Cockcroft-Gault formula:
- Male: (140 - age in years) x (wt in kg) divided by 72 x (serum creatinine in mg/dL) = CLCr (mL/min.
- Female: (140 - age in years) x (wt in kg) divided by 72 x (serum creatinine in mg/dL) x 0.85 = CLCr (mL/min).
- Negative serum pregnancy test (females of childbearing potential only).
- Males and females (of childbearing potential, i.e. less than 2 years post-menopausal) must agree to avoid pregnancy by sexual abstinence, or utilization of a highly effective method of birth control throughout the study period and for 30 days following discontinuation of study drug.
- Life expectancy greater than or equal to 1 year.
- Subjects should be available for follow up for a period of at least 48 weeks.
- The ability to understand and sign a written informed consent form, which must be obtained prior to initiation of any study procedures.
Exclusion Criteria:
- Prior antiretroviral treatment.
- Screening ALT greater than 5 x the upper limit of the normal range (ULN).
- Proven or suspected acute hepatitis in the 30 days prior to study entry. Subjects with chronic hepatitis are eligible provided that their liver transaminases (ALT) are less than 5 x ULN.
- A new AIDS defining condition diagnosed (with the exception of CD4 criteria) within 30 days of baseline.
- Previous therapy with agents with systemic myelosuppressive, pancreatoxic, hepatotoxic or cytotoxic potential within 3 months of study start or the expected need for such therapy at the time of enrollment.
- Presence of cardiomyopathy.
- Heart rate less than 40 bpm.
- Clinical symptoms potentially related to heart block (syncope, palpitations, unexplained dizziness)
- Known conduction disease.
- Third degree heart block.
- Clinically significant laboratory values that would preclude prescribing antiretroviral therapy, in the opinion of the investigator.
-
Receiving ongoing therapy with any of the following (administration of any of the following medications must be discontinued at least 30 days prior to the Baseline visit and for the duration of the study period):
- Nephrotoxic agents (aminoglycoside antibiotics, amphotericin B, cidofovir, cisplatin, foscarnet, IV pentamidine, other agents with significant nephrotoxic potential):
- Adefovir dipivoxil
- Probenecid
- Systemic chemotherapeutic agents (i.e., cancer treatment medications)
- Systemic corticosteroids
- Interleukin 2 (IL 2)
- Investigational agents (except upon approval by Gilead).
-
Drugs that are contraindicated with atazanavir and/or ritonavir including:
- midazolam
- triazolam
- ergot alkaloids
- pimozide
- proton-pump inhibitors
- H2 blockers
- lovastatin
- simvastatin
- diltiazem
- amiodarone
- bepridil
- flecainide
- propafenone
- quinidine
- St. John's Wort
- rifampin
- irinotecan
- Pregnant or lactating subjects.
- Evidence of a gastrointestinal malabsorption syndrome or chronic nausea or vomiting which may confer an inability to receive an orally administered medication.
- Current alcohol or substance abuse judged by the investigator to potentially interfere with subject adherence.
- Malignancy other than cutaneous Kaposi's sarcoma (KS) or basal cell carcinoma. Subjects with biopsy-confirmed cutaneous KS are eligible, but must not have received any systemic therapy for KS within 30 days of baseline and are not anticipated to require systemic therapy during the study.
- Active, serious infections (other than HIV 1 infection) requiring parenteral antimicrobial therapy within 15 days prior to screening.
- Prior history of significant renal or bone disease.
- Any other clinical condition or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for the study or unable to comply with the dosing requirements.
- Current imprisonment or involuntary incarceration in a medical facility for psychiatric or physical (e.g., infectious disease) illness.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00224445
United States, California | |
Gilead Sciences, Inc. | |
Foster City, California, United States, 94403 |
Study Director: | John Flaherty | Gilead Sciences |
Additional Information:
Responsible Party: | Gilead Sciences |
ClinicalTrials.gov Identifier: | NCT00224445 History of Changes |
Other Study ID Numbers: |
GS-US-164-0115 |
First Posted: | September 23, 2005 Key Record Dates |
Last Update Posted: | January 10, 2013 |
Last Verified: | January 2013 |
Keywords provided by Gilead Sciences:
Treatment Naive HIV-1 |
Additional relevant MeSH terms:
HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Ritonavir Atazanavir Sulfate Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination |
HIV Protease Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 Enzyme Inhibitors Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors |